XML 41 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Fair value of financial instruments and marketable securities - (Tables)
6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis
The following represents the fair value using the hierarchy described above for the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018:
 
 
June 30, 2019
 
 
Total
 
Quoted prices
in active
markets for
identical assets
(level 1)
 
Significant
other
observable
inputs
(level 2)
 
Significant
unobservable
inputs
(level 3)
Marketable securities
 
$
227,447

 
$

 
$
227,447

 
$

Equity investment in MRI
 
$
4,129

 
$
4,129

 
$

 
$

Stock appreciation rights liability
 
$
1,960

 
$

 
$

 
$
1,960

Deferred consideration payable
 
$
38,200

 
$

 
$
38,200

 
$

Contingent consideration payable- development and regulatory milestones
 
$
277,400


$


$


$
277,400

Contingent consideration payable- net sales milestones and royalties
 
$
58,800


$


$


$
58,800

 
 
December 31, 2018
 
 
Total
 
Quoted prices
in active
markets for
identical assets
(level 1)
 
Significant
other
observable
inputs
(level 2)
 
Significant
unobservable
inputs
(level 3)
Marketable securities
 
$
58,088


$


$
58,088


$

Stock appreciation rights liability
 
$
3,814


$


$


$
3,814

Deferred consideration payable
 
$
37,700


$


$
37,700


$

Contingent consideration payable- development and regulatory milestones
 
$
257,040


$


$


$
257,040

Contingent consideration payable- net sales milestones and royalties
 
$
53,200


$


$


$
53,200


Summary of marketable securities accounted for as available-for-sale securities
The following is a summary of marketable securities accounted for as available-for-sale securities at June 30, 2019 and December 31, 2018:
 
 
June 30, 2019
 
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
 
 
 
Gains
 
Losses
 
Commercial paper
 
$
70,185

 
$
116

 
$

 
$
70,301

Corporate debt securities
 
129,252

 
464

 
(10
)
 
129,706

Asset-backed securities
 
27,364

 
76

 

 
27,440

Total
 
$
226,801

 
$
656

 
$
(10
)
 
$
227,447

 
 
December 31, 2018
 
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
 
 
 
Gains
 
Losses
 
Commercial paper
 
$
31,657

 
$
43

 
$
(1
)
 
$
31,699

Corporate debt securities
 
26,399

 

 
(10
)
 
26,389

Total
 
$
58,056

 
$
43

 
$
(11
)
 
$
58,088


Summary of unrealized losses and fair values of available-for-sale securities in a continuous unrealized loss position
The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of June 30, 2019 are as follows:
 
 
June 30, 2019
 
 
Securities in an unrealized loss position less than 12 months
 
Securities in an unrealized loss position greater than 12 months
 
Total
 
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
Commercial paper
 
$

 
$

 
$

 
$

 
$

 
$

Corporate debt securities
 
(10
)
 
17,684

 

 

 
(10
)
 
17,684

Asset-backed securities
 

 

 

 

 

 

Total
 
$
(10
)
 
$
17,684

 
$

 
$

 
$
(10
)
 
$
17,684

The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December 31, 2018 are as follows:
 
 
December 31, 2018
 
 
Securities in an unrealized loss position less than 12 months
 
Securities in an unrealized loss position greater than 12 months
 
Total
 
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
Commercial paper
 
$
(1
)

$
1,993


$


$


$
(1
)

$
1,993

Corporate debt securities
 
(7
)

14,230


(3
)

10,087


(10
)

24,317

Total
 
$
(8
)

$
16,223


$
(3
)

$
10,087


$
(11
)

$
26,310


Schedule of marketable securities on the balance sheet
Marketable securities on the balance sheet at June 30, 2019 and December 31, 2018 mature as follows:
 
 
June 30, 2019
 
 
Less Than
12 Months
 
More Than
12 Months
Commercial paper
 
$
70,301

 
$

Corporate debt securities
 
70,192

 
59,514

Asset-backed securities
 
20,639

 
6,801

Total Marketable securities
 
$
161,132

 
$
66,315

 
 
December 31, 2018
 
 
Less Than
12 Months
 
More Than
12 Months
Commercial paper
 
$
31,699

 
$

Corporate debt securities
 
26,389

 

Total Marketable securities
 
$
58,088

 
$


Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability and SARs liability
The following significant unobservable inputs were used in the valuation of the SARs liability, and the contingent consideration payable for the periods ended June 30, 2019 and December 31, 2018:
 
 
June 30, 2019
 
 
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Range
SARs
 
$1,960
Option-pricing model
Volatility
49.70%
Risk free interest rate
2.09%
Strike price
$6.76 - $30.86
Fair value of common stock
$45.00
Expected life
0.52 years
Contingent consideration payable- development and regulatory milestones

$277,400
Probability-adjusted discounted cash flow
Potential development and regulatory milestones
$0 - $555 million
Probabilities of success
25% - 94%
Discount rates
3.8% - 5.7%
Projected years of payments
2020 - 2026
Contingent considerable payable- net sales milestones and royalties
$58,800
Option-pricing model with Monte Carlo simulation

Potential net sales milestones
$0 - $150 million
Probabilities of success
25% - 89%
Potential percentage of net sales for royalties
2% - 6%
Discount rate
14.5%
Projected years of payments
2021 - 2038
 
 
December 31, 2018
 
 
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Range
SARs
 
$3,814
Option-pricing model
Volatility
46.53% - 59.59%
Risk free interest rate
2.44% - 2.63%
Strike price
$6.76 - $30.86
Fair value of common stock
$34.32
Expected life
0.01 - 1.01 years
Contingent consideration payable- development and regulatory milestones

$257,040
Probability-adjusted discounted cash flow
Potential development and regulatory milestones
$0 - $555 million
Probabilities of success
25% - 94%
Discount rates
5.8% - 8.0%
Projected years of payments
2020 - 2026
Contingent considerable payable- net sales milestones and royalties
$53,200
Option-pricing model with Monte Carlo simulation

Potential net sales milestones
$0 - $150 million
Probabilities of success
25% - 89%
Potential percentage of net sales for royalties
2% - 6%
Discount rate
14.0%
Projected years of payments
2021 - 2038

The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss in the consolidated statements of operations. The fair value of the development and r
Fair Value Measurement Inputs and Valuation Techniques
The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuations for the SARs liability, and the contingent consideration payable for the period ended June 30, 2019. The changes in the fair value of the Company's Level 3 valuations for the period ended June 30, 2018 were immaterial.
 
 
Level 3 liabilities
 
 
SARs
 
Contingent consideration payable- development and regulatory milestones
Contingent consideration payable- net sales milestones and royalties
Beginning balance as of December 31, 2018
 
$
3,814

 
$
257,040

$
53,200

Additions
 

 


Change in fair value
 
1,961

 
20,360

5,600

Payments
 
(3,815
)
 



Ending balance as of June 30, 2019
 
$
1,960

 
$
277,400

$
58,800